NasdaqGS:TEMLife Sciences
Does Tempus AI’s (TEM) Deeper Gilead Tie Mark a Shift in Its Platform Strategy?
On 9 April 2026, Tempus AI, Inc. announced an expanded multi-year collaboration giving Gilead Sciences enterprise-wide access to its AI-driven Lens platform and broader multimodal oncology datasets, alongside integrated Tempus analytical services.
This deepened data and platform access positions Tempus more firmly inside Gilead’s oncology R&D workflows, embedding its technology in trial design, biomarker strategy, and real-world evidence generation across multiple cancer programs.
We’ll now...